Amarin Corp Plc (AMRN)

[Biobillionair]

It's actually very relevant to our current case:

As Bristol's best-selling drug before the Celgene merger—even ahead of PD-1 inhibitor Opdivo—the drug delivered $5.9 billion to the company’s top line in the first nine months of 2019. Its 25% year-over-year growth rate during the period also far exceeded Opdivo’s 10%.

As for Pfizer, Eliquis delivered a total of $3.1 billion in the first nine months, mostly in revenue from its Bristol alliance but some via direct sales in smaller markets.

In 2017, 25 generics companies told Bristol that they had filed for FDA approval of their copycats. The pair soon erected a patent wall, launching lawsuits against all those drugmakers.

That August, the U.S. Patent and Trademark Office granted Eliquis a key composition of matter patent, extending it from February 2023 to November 2026. Bristol and Pfizer have argued that’s when Eliquis generics can enter.

Our new composition patent will be placed in OB in next update.

https://www.fiercepharma.com/pharma/first-generics-to-bristol-myers-and-pfizer-s-eliquis-are-here-but-might-not-launch-until

Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=amarin.AANM.&OS=AANM/amarin&RS=AANM/amarin

Current OB:
https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=202057&Appl_type=N

The patent Use Code will also fly in the face of Du ruling...perhaps USPTO can then get involved in patent case?!

BB